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The guanosine 3,5-cyclic monophosphate (cGMP)-depen-
dent protein kinase II (cGKII) serine/threonine kinase relays
signaling through guanylyl cyclase C (GCC) to control intestinal
fluid homeostasis. Here, we report the discovery of small-
molecule inhibitors of cGKII. These inhibitors were imidazole-
aminopyrimidines, which blocked recombinant human cGKII
at submicromolar concentrations but exhibited comparatively
little activity toward the phylogenetically related protein
kinases cGKI and cAMP-dependent protein kinase (PKA).
Whereas aminopyrimidyl motifs are common in protein
kinase inhibitors, molecular modeling of these imidazole-
aminopyrimidines in the ATP-binding pocket of cGKII indi-
cated an unconventional binding mode that directs their amine
substituent into a narrowpocket delineated byhydrophobic res-
idues of the hinge and the C-helix. Crucially, this set of resi-
dues included theLeu-530 gatekeeper,which is not conserved in
cGKI and PKA. In intestinal organoids, these compounds
blocked cGKII-dependent phosphorylation of the vasodilator-
stimulated phosphoprotein (VASP). In mouse small intestinal
tissue, cGKII inhibition significantly attenuated the anion
secretory response provoked by the GCC-activating bacterial
heat-stable toxin (STa), a frequent cause of infectious secretory
diarrhea. In contrast, both PKA-dependent VASP phosphory-
lation and intestinal anion secretion were unaffected by treat-
ment with these compounds, whereas experiments with T84
cells indicated that they weakly inhibit the activity of cAMP-
hydrolyzing phosphodiesterases. As these protein kinase inhib-
itors are the first to display selective inhibition of cGKII, they
may expedite research on cGMP signaling and may aid future
development of therapeutics formanagingdiarrheal disease and
other pathogenic syndromes that involve cGKII.
The guanosine 3,5-cyclic monophosphate (cGMP)-depen-
dent protein kinase II (cGKII)2 serine/threonine kinase was
originally identified and characterized as a major cGMP target
in brush border membranes originating from rat and pig intes-
tinal epithelium and was subsequently cloned from rat brain
and intestinal tissue (1–4). Like cGKI, the only other cGMP-de-
pendent protein kinase identified in vertebrates, cGKII consists
of an N-terminal regulatory domain followed by two cGMP-
binding domains arranged in tandemand aC-terminal catalytic
domain (5). The N-terminal domain contains a leucine zipper
motif that enables dimerization and carries a myristoyl moiety
that links cGKII to lipid membranes. It is thought that cGMP
binding, through a conformational change, relieves steric inhi-
bition by a pseudosubstrate domain, located just downstream
of the leucine zipper motif, rendering the enzyme active (6).
Although cGKII forms a dimeric structure, there is no evidence
for cooperative substrate (Mg2-ATP) binding, and, based on
the close homology to the catalytic domain of PKA, eachmono-
mer is projected to form a fully functional catalytic unit. How-
ever, because the monomers are thought to be arranged in par-
allel, dimerization may stabilize membrane anchoring via the
paired myristoyl moieties. Plasma membrane anchoring has
been shown to be essential for the activation of one of its key
substrates in intestinal tissue, the cystic fibrosis transmem-
brane conductance regulator (CFTR) anion channel (7).
The gene encoding cGKII (PRKG2) is abundantly expressed
in intestinal epithelium and to a more limited extent in various
other tissues of both epithelial and nonepithelial origin. In
intestinal epithelium, cGKII relays signaling through a mem-
brane-associated, cGMP-producing enzyme, guanylyl cyclase
C (GCC). The catalytic activity of this receptor-enzyme is trig-
gered by two locally produced ligands, the peptides guanylin
and uroguanylin, but also by the heat-stable toxin (STa) pro-
duced by enterotoxigenic Escherichia coli (ETEC) strains. The
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(uro)guanylin/GCC/cGMP signaling axis stimulates intestinal
salt and water secretion through coordinate activation of CFTR-
dependent chloride and bicarbonate secretion and inhibition of
sodium uptake through sodium-proton exchanger isotype 3
(NHE3) (8). Dysregulation of this pathway may lead to luminal
dehydration and intestinal obstruction aswell as secretory diar-
rhea (8–10). Indeed, ETEC-provoked secretory diarrhea is a
significant cause of mortality in young children (11).
In addition to its role in intestinal fluid homeostasis, one of
the principal physiological roles of cGKII appears to be the reg-
ulation of the cell cycle and cellular differentiation in specific
tissues. Thus, the most prominent phenotype of cGKII defi-
ciency in rodents (and cattle) is dwarfism, which is caused by a
defect in endochondral ossification, resulting from an impaired
hypertrophic differentiation of chondrocytes (12–15).
Apart from the intestinal epithelium and growth plate carti-
lage, cGKII is found in various regions of the brain with rela-
tively high expression in specific nuclei (16). cGKII appears to
modulate synaptic transmission, and Prkg2-null mice display
subtle learning, emotional, and behavioral deficiencies (17, 18).
cGMP has several effectors other than cGKI and cGKII,
including PKA (by direct cross-activation), several phosphodi-
esterases (PDEs), and cyclic nucleotide–gated cation channels.
Therefore, to establish the cGKI or cGKII dependence of cGMP-
dependent signaling events, blockers of the cGMP-dependent
protein kinases, which either antagonize binding of cGMP or
peptide substrate, have been developed (19, 20). However, the
application of these (Rp)-cGMP isomers (carrying a sulfur
substitution on the phosphate group) and inhibitor peptides,
respectively, is for the most part limited to in vitro studies (19).
The compoundKT5823 (structurally related to the broad-spec-
ificity protein kinase inhibitor staurosporine) has been used as a
blocker of cGMP-dependent protein kinases, but its efficacy
and selectivity have been questioned (20, 21). Moreover, these
inhibitors cannot readily be used to discern between cGKI- and
cGKII-mediated effects. Here, we report the discovery of a set
of imidazole-aminopyrimidines that inhibit cGKII activity in
vitro and in native intestinal tissue.
Results
Selection of compounds
A panel of aminopyrimidines (Fig. 1) that were shown to
inhibit cGMP-dependent protein phosphorylation by recombi-
nant human cGKII by 50% at 10 mol/liter (Table 1) were
tested for their ability to inhibit cGKII in intact tissue/cells by
assessing their effect on cGMP-induced anion secretion in
mouse ileum (ex vivo). It has been shown previously that the
short-circuit current (Isc) response of mouse ileum to 8-pCPT-
cGMP fully depends on cGKII and the CFTR anion channel
(22). This test identified two compounds, AP-C5 and AP-C6,
which showed 1) potent inhibition of cGMP-dependent cGKII-
mediated protein phosphorylation and 2) effective inhibition of
cGMP-dependent, CFTR-mediated anion secretion in intesti-
nal tissue (Table 1). In contrast, compoundsAP-C1 andAP-C3,
although relatively potent inhibitors of cGKII in vitro, only
Figure 1. Chemical structure of tested aminopyrimidines.
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weakly inhibited cGKII-dependent anion secretion, suggesting
that these compounds do not effectively partition intracellu-
larly or, alternatively, are actively secreted by intestinal cells.
In vitro protein kinase inhibition
Compounds AP-C5 and AP-C6 concentration-dependently
inhibited human cGKII activity in vitro. For both compounds,
half-maximal inhibition was attained at submicromolar levels
(Fig. 2A). To evaluate the selectivity of these two compounds,
we also assessed their activity toward cGKI and PKA, i.e. pro-
tein kinases that are phylogenetically and structurally closely
related to cGKII. This showed that the potency of inhibition of
cGKI and PKA was markedly lower than of cGKII (Fig. 2A).
Most small-molecule inhibitors of protein kinases target the
ATP-binding pocket (21). Consistent with this notion, we
observed that the level of cGKII inhibition caused by AP-C5 or
AP-C6 depended on the ATP concentration (Fig. 2B). These
results suggest that these compounds compete with substrate
for binding to the catalytic domain of cGKII. Interestingly, the
reported Km(ATP) values of cGKI and PKA are approximately
10-fold lower than that of cGKII (23, 24). Assuming that these
related enzymes are also inhibited through an ATP-competi-
tive mechanism, this suggests that these compounds would be
highly cGKII-selective at cellular ATP levels.
Molecularmodeling of ligand docking in the ATP-binding
pocket
In the proposed ligand docking solution (Fig. 3), the three
linear aromatic rings of AP-C5 are wedged between hydropho-
bic residues in the G-loop and similar residues flanking the
DFG and HRD motifs, binding through hydrogen– interac-
tions with Val-467, Ile-583, and Val-593. The aminopyrimidine
ring forms hydrogen bonds with catalytic residues Lys-482 and
Glu-501, and the imidazole ring acts as a hydrogen-bond accep-
tor to the backbone NH group of Cys-533 in the hinge region.
This bindingmode directs the acetenyl amine substituent into a
small pocket formed by Leu-505 in the C-helix and the Leu-
530 gatekeeper. Gatekeeper residues delimit the size of the
ATP-binding pocket and are known to govern the affinity for
substrates and inhibitors/modulators of protein kinases (21,
25). In cGKII, the pocket formed by Leu-505 and Leu-530 can
accommodate acetenyl (AP-C5) or hydroxyl (AP-C6) substitu-
ents but not the larger furanyl moiety of AP-C7, accounting for
themodest activity of the latter compound. In addition, because
this pocket is linedwith further hydrophobic residues (Val-514,
Val-593, and Phe-595), the acetenyl group of AP-C5 is pre-
ferred above the more polar alcohol of AP-C6.
Inhibition of intestinal cGKII
The vasodilator-stimulated phosphoprotein (VASP),
through its association with actin filaments, plays an important
role in cytoskeletal dynamics (26). Like cGKII andCFTR, VASP
is located at the apical aspect of intestinal epithelial cells, and it
has been shown that VASP is a substrate of cGMP-dependent
protein kinases (27, 28). We found that incubation of ileal
organoid cultures with 8-pCPT-cGMP markedly enhanced
phosphorylation of VASP at Ser-239 (conforming to the topol-
ogy of human VASP; the equivalent residue in murine VASP is
actually at position 235), which is the site preferentially phos-
phorylated by cGMP-dependent protein kinases (Fig. 4) (27).
This 8-pCPT-cGMP–dependent VASP phosphorylation was
blocked by AP-C5, attesting the action of this compound on
cellular cGKII. Consistent with its low activity toward PKA in
vitro, AP-C5 did not block vasoactive intestinal peptide (VIP)-
stimulated, PKA-mediated Ser-239 phosphorylation (Fig. 4).
In mouse ileum, AP-C5 and AP-C6 concentration-depen-
dently inhibited 8-pCPT-cGMP–induced anion secretion (Fig.
5). Half-maximal inhibition was attained at concentrations
roughly 10 times higher than anticipated, based on the esti-
mated pIC50 values for cGKII inhibition at cellular ATP levels
(see Fig. 2, inset). This may indicate that, at high levels, cGKII
activity does not limit anion secretion because saturating levels
of substrate phosphorylation are attained. Furthermore, the
activity of these substratesmay not limit the rate of anion secre-
tion. This holds true for intestinal CFTR as it has been shown
that50% of the cellular pool is required for a full-anion secre-
tory response (29). Consequently, at the concentration where
half-maximal inhibition of anion secretion occurs, the level of
cGKII activity and substrate phosphorylation may be well
below 50% of control values, and the level of cGKII inhibition
attained may be in closer agreement with the data obtained in
vitro than is immediately apparent.
The STa produced by ETEC provokes secretory diarrhea by
potent activation of GCC (8). It has been shown that the anion
secretory response elicited by STa is reduced by approximately
80% in cGKII-deficient mice compared with normal animals
(22). Congruent with this partial cGKII dependence, we found
that AP-C5 and AP-C6 partially blocked the STa-mediated Isc
response in mouse ileum (Fig. 6).
Effect of AP-C5 and AP-C6 on PDE activity
In mouse ileum, we found that these compounds, at a con-
centration 50 mol/liter, did not inhibit the anion secretory
response elicited by the cAMP/PKA agonist forskolin (Fig. 7A).
In fact, we found that AP-C5 potentiated the anion secretory
response to forskolin of ileum (Fig. 7B). In view of this potenti-
ation, we speculated that this compound, and its close analog
AP-C6, might elevate cAMP levels, conceivably through inhi-
bition of PDE activity. Consistent with this supposition, we
Table 1
Identification of compounds that inhibit cGKII activity in intestinal
tissue
For assessing pharmacological inhibition of intestinal cGKII-dependent anion
secretion, compounds were selected with pIC50 (log10 of the half-maximal inhib-
itory concentration)5 as assessed in assays of recombinant human cGKII-medi-
ated protein phosphorylation. Their effect on cGKII-dependent anion secretionwas
assessed on mouse ileum in an Ussing chamber setup. Inhibition of 8-pCPT-cGMP
(50 mol/liter)–dependent anion secretion was calculated as the residual Isc
response 20min after addition of compound (20mol/liter) relative to the initial full
Isc response assessed just before addition of the compound. The number of biolog-
ical replicates is indicated in parentheses.
Compound
pIC50
in vitro
8-pCPT-cGMP–dependent anion
secretion (% inhibition)
AP-C1 6.5 1.7 10.8 (3)
AP-C2 5.2 7.7 16.7 (3)
AP-C3 6.3 7.6 10.0 (4)
AP-C4 5.2 3.7 5.2 (3)
AP-C5 7.2 72.0 7.0 (4)
AP-C6 6.5 34.0 12.7 (4)
AP-C7 5.0 5.5 5.6 (4)
Inhibition of intestinal cGKII
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found that in T84 cells these compounds moderately enhanced
cAMP levels but only in the presence of forskolin (i.e. of adeny-
lyl cyclase activity; Fig. 7C). This strongly suggests that these
compounds, at high concentrations, potentiate cAMP signaling
through inhibition of PDE activity.
Discussion
We report the discovery of small-molecule inhibitors of
cGKII that block protein phosphorylation and the ensuing
ion secretory responses in the small intestinal epithelium
elicited by cGMP-linked signal transduction pathways. In
vitro, these imidazole-aminopyrimidines inhibited human
cGKII at submicromolar levels. In contrast, these com-
pounds showed little activity toward phylogenetically related
ACG-type serine/threonine kinases (cGKI and PKA). To our
knowledge, the presently developed compounds are the first to
display selectivity in this respect and activity in native (intesti-
nal) tissue.
Our kinetic analysis indicates that these compounds interact
with the catalytic (ATP-binding) domain of cGKII. Aminopy-
rimidyl motifs are relatively common in this type of protein
kinase inhibitors as these readily form hydrogen bonds with
residues in the hinge region of the catalytic domain. However,
molecular modeling indicated that the binding mode of the
present set of compounds is more unusual as the aminopyrimi-
dyl ring is projected to interact with residues in the catalytic
loop. A similar, reversed orientation has previously been
described for blockers of PDK1 and PIM1 (30, 31). This orien-
tation guides the amine substituent into a small pocket, delim-
ited by the Leu-505 and Leu-530 (gatekeeper) residues. These
residues form a selectivity pocket that permits docking of im-
idazole-aminopyrimidines with relatively small substituents,
such as AP-C5 and AP-C6. Importantly, both cGKI (Met-438)
and PKA (Met-121) contain slightly bulkier gatekeeper resi-
dues, which preclude effective docking of the present set of
ligands. In addition, in cGKI, anothermethionine residue (Met-
413) replaces the Leu-505 in the C-helix of cGKII, further
restricting access to the selectivity pocket. Thus, the unusual
bindingmode ofAP-C5 accounts for both its potency and selec-
tivity.High affinity results frompolar interactionswith residues
in both the hinge and catalytic loops and hydrophobic interac-
tions across the imidazole-phenylpyrimidine core, whereas the
positioning of the amine substituent into a tight pocket, which
only accommodates small, preferentially hydrophobic groups,
confers selectivity.
In mouse small intestine, these compounds effectively
blocked 8-pCPT-cGMP–dependent VASP phosphorylation
and anion secretion but only partially inhibited the STa-pro-
voked anion secretory response. These data corroborate previ-
ous studies on cGKII-deficient mice showing that the response
to STa is only approximately 80% dependent on cGKII and that,
in addition, STa signals through cGKII-independent routes.
Chiefly, cGMP is thought to also enhance PKA signaling
through competitive inhibition of the cAMP-hydrolyzing PDE
type 3 (PDE3), but direct cross-activation of PKA may also
occur (22, 32). Importantly, in contrast to cGMP itself, imidaz-
ole ring–substituted cGMP analogs do not block PDE activity
(nor are they readily hydrolyzed by PDEs) or activate PKA.
Consequently, the (prosecretory) effects of 8-pCPT-cGMP in
the intestine are fully cGKII-dependent and amenable to inhi-
bition by our compounds.
Figure 2. Inhibition of PKA, cGKI, and cGKII by compounds AP-C5 and AP-C6. A, phosphorylation of peptide substrate by PKA, cGKI, and cGKII was
assessed at compound concentrations ranging between 1.0109 and 3.0104 mol/liter. The concentration dependence of enzyme inhibition was
analyzed, yielding the pIC50 values shown in the inset. The number of technical replicates (n) is indicated in parentheses. Combined with the Km(ATP)
values determined in a separate set of experiments, these were used to estimate the pIC50 values at cellular ATP levels (44). B, rate of cGKII-dependent
32Pi-peptide production (V) as a function of the ATP concentration in the absence (control) or presence of AP-C5 (0.1mol/liter) or AP-C6 (0.5mol/liter).
Data were derived from a single experiment performed in triplicate. *, no complete inhibition was attained in the concentration range tested. Error bars
represent S.D.
Inhibition of intestinal cGKII
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Apart from by a redundancy in prosecretory cGMP-depen-
dent signaling pathways, the moderate efficacy of these cGKII
inhibitors toward the STa-dependent Isc response of ileummay
be compounded by their weak inhibition of PDEs, which may
derive from their structural resemblance to previously identi-
fied PDE blockers (33). Thus, at high concentrations, they
would have opposing effects on the cGMP-mediated secretory
response by concurrent inhibition of cGKII and PDE activity.
Figure 3. Schematic of the docking of AP-C5 at the ATP-binding domain of cGKII. This model was based on the X-ray structure of the highly homologous
catalytic subunit of PKA. Thenumberedaminoacidsdesignate residues involved in liganddocking. Crucial structural elements of the active site arehighlighted
as follows: G-loop, green; Hyd1 (AXK 3-strand) residues, orange; C-helix, magenta; hinge, blue; HRD motif, red; DFG motif, turquoise. The inset shows an
alignment of the ATP-binding pockets of cGKI, cGKII, and PKA. *, residues that are within a 4.5-Å radius of the ligand. A boxed asterisk indicates a residue that is
not conserved in cGKI and/or PKA.
Figure 4. cGKII-, but not PKA-, dependent VASP phosphorylation in intestinal organoids is blocked by AP-C5. VASP phosphorylation at Ser-239 was
detectedby immunoblotting inmouse intestinal organoids.A, effect ofAP-C5on8-pCPT-cGMP–andVIP-dependentVASPphosphorylation (p-VASP). Note that
phosphorylation of Ser-157, a PKA-preferred residue, leads to a shift in the electrophoreticmobility of VASP (upper band of the doublet).Numerals to the left of
the blot refer to themolecular mass (kDa) of protein standards shown in the left outer lane. B, aggregate data depicting the fluorescence intensity of the VASP
signal relative to the villin signal of the same sample. Each data point represents one technical replicate. **, p 0.01. Error bars represent S.D.
Inhibition of intestinal cGKII
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Suppression of CFTR phosphorylation may effectively reduce
fluid secretion as was shown for direct pharmacological CFTR
blockage and for GCC inhibition (34, 35). However, ETEC/
STa–provoked secretory diarrhea not only results from anom-
alousCFTRactivation but also from inhibition ofNHE3 activity
(i.e. an antiabsorptive action) (8). Like cGKII, NHE3 is highly
expressed in the villus region of the intestinal epithelium and
was shown to be inhibited in the presence of 8-pCPT-cGMP or
STa (36). Consequently, we infer that, upon ETEC colonization
of the gut, pharmacological cGKII blockage would stimulate
salt and fluid absorption by restoring NHE3 activity.
In addition to its established role in controlling the intestinal
fluid balance and the cell cycle, evidence accrued over the last
decade points toward various other functions of cGKII in phys-
iology. These often intriguing new prospects, such as cGKII’s
potential role in (feeding) behavior and psychosocial disorders,
warrant further research (17, 18, 37, 38). We propose that the
compounds presented here may help to substantiate and fur-
ther delimit the role of cGKII in such processes.
Experimental procedures
Animals
Mice (FVB) were maintained in an environmentally con-
trolled facility at the Erasmus MC, Rotterdam, The Nether-
lands. All experiments were performed on animals 12–26
weeks of age andwere approved of by the Ethical Committee for
Animal Experiments of the Erasmus MC.
Protein kinase assays
For assays performed on recombinant full-length human
cGKI (Promega) or cGKII (His-tagged; produced through the
baculovirus insect cell expression system), enzyme (100 g/li-
ter) was added to assay solution containing Na-cGMP (50
mol/liter), DTT (5 mmol/liter), Tris/HCl, pH 7.4 (20 mmol/
liter), MgCl2 (5 mmol/liter), BSA (25 mg/liter), and peptide
Figure 5. Concentration-dependent inhibition of cGKII-dependent anion secretion in mouse ileum by AP-C5 and AP-C6. A, representative Ussing
chamber experiment illustrating the procedure for testing inhibition of cGKII-dependent, CFTR-mediated anion secretion. Anion secretion was stimulated by
additionof 8-pCPT-cGMP. After the ensuing Isc responsehad reached aplateau, compoundor vehicle (DMSO)was added to the luminal bath. Inhibitionof ileal
anion secretionwas calculatedas the reduction in the Isc response20minafter additionof compound relative to the initial full Isc response assessed just before
addition of the compound. B, inhibition of 8-pCPT-cGMP–dependent anion secretion as a function of compound concentration. Data of six (AP-C5) or five
(AP-C6) biological replicates were analyzed by nonlinear regression, yielding the IC50 values (mean with 95% confidence interval in square brackets) shown in
the inset. Error bars represent S.D.
Figure 6. Inhibition of cGKII by AP-C5 or AP-C6 reduces STa-dependent
anion secretion in mouse ileum. A, representative experiment illustrating
the procedure for testing inhibition of STa-dependent anion secretion. Note
that in the sustained presence of compound the tissue remained responsive
to forskolin. B, both compounds (20 mol/liter) reduced STa-dependent
anion secretion relative to a solvent (0.1% DMSO) control. Each data point
represents one biological replicate. ***, p  0.001 versus DMSO. Error bars
represent S.D.
Figure 7. AP-C5 andAP-C6 potentiate cAMP signaling by PDE inhibition.
A, in ileum, AP-C5 and AP-C6 did not reduce the Isc response elicited by fors-
kolin (10 mol/liter). Each data point represents one biological replicate. B,
forskolin-dependent anion secretion in the presence of AP-C5 (50mol/liter)
or vehicle (DMSO). AP-C5 lowered the forskolin concentration required to
attain half-maximal stimulation of the Isc (p 0.0001; inset). Data of 10 bio-
logical replicates per group were analyzed. C, compounds AP-C5 and AP-C6
potentiate forskolin-induced cAMP production in T84 cells. T84 cells were
incubated with cGKII inhibitor compound (50 mol/liter), DMSO (0.1%), or
isobutylmethylxanthine (IBMX) (0.5mmol/liter) in the absence or presence of
forskolin (0.5 mol/liter). Each data point represents one technical replicate.
*, p  0.05; **, p  0.01; ***, p  0.001 versus forskolin/DMSO. Error bars
represent S.D.
Inhibition of intestinal cGKII
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substrate 2A3 (RRKVSKQE; 25mg/liter) (39). For assays on the
PKA catalytic subunit (25 g/liter; Promega), the peptide sub-
strate kemptide (LRRASLG; 25 mg/liter) was used, and Na-
cGMP and DTT were omitted from the assay solution. Test
compounds were added from stocks prepared in DMSO, and
their effect was evaluated relative to the appropriate vehicle
control (2% DMSO). Reactions (1 h at 22 °C) were started by
addition of [-32P]ATP (100 MBq/liter; total ATP concentra-
tion as indicated in Fig. 2) and quenched by adding EDTA (100
mmol/liter). Peptide substrate was collected on cellulose phos-
phate cation exchanger (MAPHN0B50, Millipore) prerinsed
with 1% H3PO4. After washing five times with 1% H3PO4, the
radioactivity collected on the filters was quantified by liquid
scintillation counting. For data analysis, median values, derived
from assays performed in triplicate, were used.
Molecularmodeling of ligand docking
Because the X-ray structure of the cGKII catalytic domain is
unresolved, we used a high-resolution (1.6-Å) X-ray structure
of the PKA catalytic domain (Protein Data Bank code 4WB5) as
a structural template for modeling of ligand binding (40). The
cGKII (amino acids 453–711; UniProt accession number
Q13237) and PKA (UniProt accession number P17612) cata-
lytic domains were aligned (showing 51% sequence identity),
and a homology model of the cGKII catalytic domain was built
using Molecular Operating Environment (MOE) (v2016.0802;
Chemical ComputingGroup,Montreal, Canada). The resulting
model had a low backbone root-mean-square deviation in the
binding site, no stereochemical violations or structural clashes,
and suitable backbone and side-chain dihedral angles. Model-
ing of the ligands in ADMET Predictor (v7; Simulations Plus,
Lancaster, CA) showed that AP-C5 and AP-C6 are uncharged
at neutral pH values (pKa  5.3). Induced fit docking of the
ligand in the ATP-binding site, defined as all amino acids and
those bonded to them within a 4.5-Å radius of the ligand, was
performed using MOE.
Ussing chamber assays
Collection of murine intestinal tissue and Ussing chamber
assays were performed as described elsewhere (41). Tissue
was incubated in modified Meyler solution (128 mmol/liter
NaCl, 4.7 mmol/liter KCl, 1.3 mmol/liter CaCl2, 1.0 mmol/liter
MgCl2, 0.3 mmol/liter Na2HPO4, 0.4 mmol/liter NaH2PO4, 20
mmol/liter NaHCO3, 10 mmol/liter HEPES), supplemented
with glucose (10mmol/liter; added solely to the serosal bathing
solution) in 95%O2, 5%CO2, pH7.3, at 37 °C. CFTR-dependent
anion secretion was stimulated by addition of the adenylyl
cyclase activator forskolin (Sigma-Aldrich), STa (added to the
luminal bathing solution only; Bachem), or themembrane-per-
meable cGMP analog 8-pCPT-cGMP (Sigma-Aldrich). Data
shown represent Isc measurements, obtained by clamping of
the transepithelial potential difference at 0 mV.
VASP serine 239 phosphorylation
Organoids derived from mouse ileum were cultured as
described elsewhere (42). Organoids (5 days after seeding) were
incubated in advanced DMEM/F-12 (Invitrogen) with VIP (50
nmol/liter; Bachem) or 8-pCPT-cGMP (50 mol/liter) and in
the presence or absence of compound AP-C5 (20 mol/liter;
Fig. 1) in 5% CO2, pH 7.3, at 37 °C. After 30 min, medium was
aspirated, and organoids were collected in ice-cold PBS supple-
mented with NaF (1 mmol/liter) and Na3VO4 (1 mmol/liter).
After centrifugation (300  g, 5 min), pelleted organoids were
lysed in NaCl (150 mmol/liter), Tris/HCl, pH 7.6 (25 mmol/
liter), Triton X-100 (1%), sodium deoxycholate (1%), SDS
(0.1%), NaF (5 mmol/liter), Na3VO4 (3 mmol/liter) supple-
mented with a protease inhibitor mixture (Roche Applied Sci-
ence). Lysates were subjected to SDS-PAGE, and proteins were
transferred to nitrocellulose membrane. Ser-239–phosphory-
lated VASP was detected by Western blot analysis (CST3114,
Cell Signaling Technology). A fluorescent dye–labeled second-
ary antibody and the Odyssey IR imaging system (Application
software 3, LI-COR Biosciences) were used for quantitation.
Detection of villin (SC58897, Santa Cruz Biotechnology) served
as a reference.
Measurement of cellular cAMP levels
T84 cells were grown to 80% confluence in 12-well culture
plates (43). Cells, washed twice in modified Meyler solution,
were incubated in modified Meyler solution supplemented
with glucose (10 mmol/liter) and AP-C5 or AP-C6 (Fig. 1) or
the broad-specificity PDE inhibitor isobutylmethylxanthine
(Sigma-Aldrich) in the absence or presence of forskolin for 10
min in 5% CO2 at 37 °C. Reactions were quenched by adding
ice-cold ethanol (70%), and cAMP levels were assayed as
described elsewhere (41).
Data analysis
The concentration dependence of protein kinase inhibition,
Isc responses, and enzyme kinetics were analyzed by nonlinear
regression (GraphPad Prism 5.0, GraphPad Software). Derived
EC50 and IC50 values are presented asmean and 95%confidence
interval. The Cheng–Prusoff equation was used to estimate
pIC50 values at cellular ATP levels (44). VASP phosphorylation,
inhibition of STa-dependent anion secretion, and cAMP pro-
duction in T84 cells were evaluated by one-way analysis of vari-
ance followed by Tukey’s multiple comparisons test (GraphPad
Prism 5.0). Data are presented as mean S.D.
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